MA31536B1 - Sels d'amines d'un antagoniste de crth2 - Google Patents

Sels d'amines d'un antagoniste de crth2

Info

Publication number
MA31536B1
MA31536B1 MA32540A MA32540A MA31536B1 MA 31536 B1 MA31536 B1 MA 31536B1 MA 32540 A MA32540 A MA 32540A MA 32540 A MA32540 A MA 32540A MA 31536 B1 MA31536 B1 MA 31536B1
Authority
MA
Morocco
Prior art keywords
salts
amines
crth2 antagonist
crth2
ceetic
Prior art date
Application number
MA32540A
Other languages
English (en)
Inventor
Tai Wei Ly
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31536(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of MA31536B1 publication Critical patent/MA31536B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION PORTE SUR DES SELS D'AMINES D'ACIDE {4,6-BIS(DIMÉTHYLAMINO)-2-(4-(4-(TRIFLUOROMÉTHYL)BENZAMIDO)BENZYL)PYRIMIDIN-5-YL}-ACÉTIQUE, SUR DES PROCÉDÉS PERMETTANT DE LES PRÉPARER, SUR DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET SUR LEUR UTILISATION POUR LE TRAITEMENT, LA PRÉVENTION OU L'AMÉLIORATION D'UN OU PLUSIEURS SYMPTÔME D'UN TROUBLE OU D'UNE MALADIE À MÉDIATION PAR CRTH2.
MA32540A 2007-06-21 2010-01-19 Sels d'amines d'un antagoniste de crth2 MA31536B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93673607P 2007-06-21 2007-06-21

Publications (1)

Publication Number Publication Date
MA31536B1 true MA31536B1 (fr) 2010-07-01

Family

ID=39731477

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32540A MA31536B1 (fr) 2007-06-21 2010-01-19 Sels d'amines d'un antagoniste de crth2

Country Status (22)

Country Link
US (1) US8278310B2 (fr)
EP (1) EP2176240A1 (fr)
JP (1) JP6006914B2 (fr)
KR (1) KR20100039350A (fr)
CN (4) CN102875478A (fr)
AR (1) AR067118A1 (fr)
BR (1) BRPI0812597A2 (fr)
CA (1) CA2690436A1 (fr)
CL (1) CL2008001817A1 (fr)
CO (1) CO6251286A2 (fr)
EC (1) ECSP109851A (fr)
IL (1) IL202755A0 (fr)
MA (1) MA31536B1 (fr)
MX (1) MX2009013813A (fr)
MY (1) MY149005A (fr)
NZ (1) NZ581856A (fr)
RU (1) RU2468013C2 (fr)
TN (1) TN2009000517A1 (fr)
TW (1) TWI419693B (fr)
UA (1) UA101326C2 (fr)
WO (1) WO2008156781A1 (fr)
ZA (1) ZA200909110B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
CA2735722A1 (fr) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals, Inc. Derives d'acide pyrimidin-5-ylacetique enrichis en isotopes en tant qu'antagonistes de crth2
JP2012517405A (ja) * 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
WO2011005645A1 (fr) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Polymorphe de [4,6-bis(diméthylamino)-2-(4-{[4-(trifluorométhyl)benzoyl]amino}benzyl)pyrimidin-5-yl] acétique
MX2012006003A (es) * 2009-11-24 2012-06-19 Boehringer Ingelheim Int Procedimiento para preparar un polimorfo de la sal de colina de [4,6-bis(dimetilamino)-2-(4-{[4-(trifluorometil)-benzoil]amino}be ncil)pirimidin-5-ilo].
JP2013512239A (ja) 2009-11-24 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリミジン−５−イル酢酸誘導体の新規な塩の形態
EP2598145A1 (fr) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Composition pharmaceutique pour le traitement de maladies respiratoires et inflammatoires
JP2013535456A (ja) * 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
EP2790696A1 (fr) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combinaison d'un antagoniste de crth2 et d'un inhibiteur de pompe à protons pour le traitement de l' sophagite à éosinophiles
WO2015124168A1 (fr) 2014-02-18 2015-08-27 Bekey A/S Contrôle d'accès à un emplacement
RU2019128534A (ru) 2017-02-15 2021-03-16 Наньян Текнолоджикал Юниверсити Химические соединения для лечения туберкулеза

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12252A (en) * 2000-04-26 2006-05-11 Warner Lambert Co Antihypertensive agents and use.
US7078690B2 (en) * 2002-02-04 2006-07-18 Applied Materials, Israel, Ltd. Monitoring of contact hole production
DE60303238T2 (de) * 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
RU2007141206A (ru) * 2005-04-07 2009-05-20 Тейдзин Фарма Лимитед (Jp) Кристаллическая форма производного аминопирролидина и способ ее получения
CN103172573A (zh) * 2007-06-21 2013-06-26 艾克提麦斯医药品有限公司 Crth2 拮抗剂的微粒
CA2735722A1 (fr) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals, Inc. Derives d'acide pyrimidin-5-ylacetique enrichis en isotopes en tant qu'antagonistes de crth2

Also Published As

Publication number Publication date
CL2008001817A1 (es) 2009-03-13
UA101326C2 (en) 2013-03-25
WO2008156781A1 (fr) 2008-12-24
AR067118A1 (es) 2009-09-30
CN102898380A (zh) 2013-01-30
ECSP109851A (es) 2010-03-31
BRPI0812597A2 (pt) 2015-02-18
CN102875478A (zh) 2013-01-16
US20110034482A1 (en) 2011-02-10
HK1144940A1 (en) 2011-03-18
JP6006914B2 (ja) 2016-10-12
EP2176240A1 (fr) 2010-04-21
AU2008266854A1 (en) 2008-12-24
TW200911261A (en) 2009-03-16
KR20100039350A (ko) 2010-04-15
CA2690436A1 (fr) 2008-12-24
MY149005A (en) 2013-06-28
TWI419693B (zh) 2013-12-21
IL202755A0 (en) 2010-06-30
RU2010101795A (ru) 2011-07-27
CO6251286A2 (es) 2011-02-21
US8278310B2 (en) 2012-10-02
ZA200909110B (en) 2011-03-30
NZ581856A (en) 2011-05-27
CN102898381A (zh) 2013-01-30
JP2010530426A (ja) 2010-09-09
TN2009000517A1 (en) 2011-03-31
MX2009013813A (es) 2010-02-03
CN101772489A (zh) 2010-07-07
CN101772489B (zh) 2013-02-20
RU2468013C2 (ru) 2012-11-27

Similar Documents

Publication Publication Date Title
MA31536B1 (fr) Sels d'amines d'un antagoniste de crth2
MA31534B1 (fr) Particules d'antagoniste de crth2
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MA42145A (fr) Triazoles agonistes du récepteur apj
UA96764C2 (ru) Производные бензимидазола, полезные в лечении расстройств, связанных с рецептором trpvl
MA33926B1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
MA45920A (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
PE20121313A1 (es) Derivados de 4-aminociclohexano sustituidos
NO20075087L (no) Kombinasjoner, metoder og sammensetninger for behandling av cancer
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
BRPI0509298A (pt) composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
MA31311B1 (fr) Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p)
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
SI2185155T1 (en) Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors
TN2011000252A1 (fr) Lactames servant d'inhibiteurs de beta-secretase
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
UY29219A1 (es) Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida
MA69856B1 (fr) Formes de sel citrate d'un agoniste du récepteur muscarinique
RU2427573C2 (ru) Новые производные бензимидазола в качестве ингибиторов ваниллоидного рецептора 1 (vr1)
MY147474A (en) 1-[(4-[benzoyl(methyl)amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1
Procopiou et al. The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis